Blincyto converted to full approval
The FDA converted Blincyto to full approval for minimal residual disease in B‑cell acute lymphoblastic leukemia, moving the indication from provisional status to an established approval. That change formalises a longer‑term regulatory commitment for lifecycle evidence and safety oversight. (managedhealthcareexecutive.com)
Blincyto now has full United States approval for patients with B-cell acute lymphoblastic leukemia who are in remission but still have measurable leftover disease. (fda.gov) That leftover disease is called minimal residual disease, or measurable residual disease: leukemia cells so scarce they cannot be seen under a microscope but can still be found by sensitive tests. In acute lymphoblastic leukemia, those trace cells signal a higher risk that the cancer will return. (fda.gov) The Food and Drug Administration first cleared this use on March 29, 2018, under accelerated approval for adults and children with B-cell precursor acute lymphoblastic leukemia in first or second complete remission and minimal residual disease of at least 0.1%. The current prescribing information lists that same indication for adults and children age 1 month and older, without accelerated-approval language. (fda.gov) (accessdata.fda.gov) Blincyto is blinatumomab, an immune drug built like a molecular bridge. It binds CD19 on leukemia cells and CD3 on T cells, pulling the patient’s immune cells close enough to attack the leukemia. (fda.gov) The original 2018 approval rested on a single-arm study in patients whose marrow still showed at least 1 leukemia cell in 1,000 cells. In the BLAST study, 88 of 113 evaluable patients, or 78%, reached a complete minimal residual disease response after one cycle. (fda.gov) (pubmed.ncbi.nlm.nih.gov) That study also reported a median overall survival of 36.5 months in the Philadelphia chromosome-negative group, and patients who cleared measurable disease lived longer without relapse than nonresponders. Those were the signals regulators used while waiting for longer-term evidence. (pubmed.ncbi.nlm.nih.gov) Since then, blinatumomab has moved earlier in treatment. In a phase 3 trial published in 2024, adults aged 30 to 70 with BCR::ABL1-negative B-cell precursor acute lymphoblastic leukemia and measurable-residual-disease-negative remission had 3-year overall survival of 85% with blinatumomab plus consolidation chemotherapy versus 68% with chemotherapy alone. (nejm.org) The label still carries a boxed warning for cytokine release syndrome and neurologic toxicity, including immune effector cell-associated neurotoxicity syndrome. For the minimal-residual-disease indication, the label recommends hospitalization for the first 3 days of cycle 1 and the first 2 days of cycle 2. (accessdata.fda.gov) Blincyto was first approved in the United States in 2014 for relapsed or refractory disease, and the label was expanded again in June 2024 for use during consolidation chemotherapy regardless of measurable residual disease status. The full approval in minimal residual disease turns one of the drug’s older provisional uses into a permanent one. (accessdata.fda.gov) (amgen.com)
